UBS Group
LKFT

UBS Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

UBS Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.26M Sell
175,289
-174,155
-50% -$5.77M ﹤0.01% 4036
2025
Q4 		$11.4M Buy
349,444
+196,445
+128% +$6.34M ﹤0.01% 3150
2025
Q3 		$5.3M Sell
152,999
-85,525
-36% -$2.74M ﹤0.01% 3977
2025
Q2 		$6.68M Buy
238,524
+129,513
+119% +$3.47M ﹤0.01% 3571
2025
Q1 		$2.74M Buy
109,011
+33,432
+44% +$845K ﹤0.01% 4410
2024
Q4 		$2.08M Buy
75,579
+74,597
+7,596% +$2.08M ﹤0.01% 4682
2024
Q3 		$28.3K Sell
982
-74
-7% -$2.02K ﹤0.01% 7154
2024
Q2 		$26.2K Sell
1,056
-321
-23% -$9.11K ﹤0.01% 7132
2024
Q1 		$44.3K Sell
1,377
-582
-30% -$21.6K ﹤0.01% 6566
2023
Q4 		$79.6K Buy
1,959
+1,280
+189% +$47.1K ﹤0.01% 6309
2023
Q3 		$23.5K Sell
679
-621
-48% -$24.2K ﹤0.01% 6720
2023
Q2 		$52.9K Buy
1,300
+529
+69% +$21.6K ﹤0.01% 6444
2023
Q1 		$29.8K Sell
771
-2,832
-79% -$116K ﹤0.01% 6806
2022
Q4 		$160K Buy
3,603
+2,094
+139% +$88.1K ﹤0.01% 5661
2022
Q3 		$64K Buy
1,509
+557
+59% +$28.5K ﹤0.01% 6105
2022
Q2 		$53K Buy
952
+146
+18% +$8.66K ﹤0.01% 5865
2022
Q1 		$50K Sell
806
-65,396
-99% -$4M ﹤0.01% 6494
2021
Q4 		$3.65M Buy
66,202
+65,334
+7,527% +$3.41M ﹤0.01% 3179
2021
Q3 		$45K Sell
868
-1,297
-60% -$77K ﹤0.01% 6418
2021
Q2 		$150K Buy
2,165
+1,232
+132% +$94K ﹤0.01% 5570
2021
Q1 		$71K Sell
933
-817
-47% -$75.3K ﹤0.01% 6221
2020
Q4 		$173K Buy
1,750
+1,057
+153% +$129K ﹤0.01% 5322
2020
Q3 		$99K Sell
693
-692
-50% -$115K ﹤0.01% 5188
2020
Q2 		$273K Buy
1,385
+742
+115% +$154K ﹤0.01% 4581
2020
Q1 		$126K Sell
643
-121
-16% -$26K ﹤0.01% 5081
2019
Q4 		$158K Sell
764
-2,303
-75% -$426K ﹤0.01% 5749
2019
Q3 		$468K Buy
3,067
+380
+14% +$62.3K ﹤0.01% 4627
2019
Q2 		$346K Sell
2,687
-406
-13% -$48.2K ﹤0.01% 4551
2019
Q1 		$364K Buy
3,093
+1,583
+105% +$160K ﹤0.01% 4257
2018
Q4 		$139K Sell
1,510
-127
-8% -$12.9K ﹤0.01% 5253
2018
Q3 		$184K Sell
1,637
-313
-16% -$33.1K ﹤0.01% 5130
2018
Q2 		$180K Buy
1,950
+748
+62% +$72.6K ﹤0.01% 5031
2018
Q1 		$120K Sell
1,202
-395
-25% -$42.6K ﹤0.01% 5104
2017
Q4 		$150K Buy
1,597
+447
+39% +$42.3K ﹤0.01% 5110
2017
Q3 		$117K Sell
1,150
-1,227
-52% -$107K ﹤0.01% 5218
2017
Q2 		$182K Sell
2,377
-1,145
-33% -$96.3K ﹤0.01% 4799
2017
Q1 		$303K Buy
3,522
+2,477
+237% +$178K ﹤0.01% 4380
2016
Q4 		$67K Sell
1,045
-6,717
-87% -$413K ﹤0.01% 5596
2016
Q3 		$502K Buy
7,762
+2,842
+58% +$160K ﹤0.01% 3924
2016
Q2 		$273K Buy
4,920
+496
+11% +$24.9K ﹤0.01% 4326
2016
Q1 		$185K Sell
4,424
-32
-0.7% -$1.49K ﹤0.01% 4539
2015
Q4 		$280K Buy
4,456
+1,046
+31% +$53.5K ﹤0.01% 4412
2015
Q3 		$139K Buy
3,410
+910
+36% +$52.4K ﹤0.01% 4944
2015
Q2 		$129K Buy
+2,500
New +$133K ﹤0.01% 5209

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's LKFT Position: Q1 2026 in Review

UBS Group reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 50% in Q1 2026, selling an estimated $5.77M and leaving 175,289 shares worth $5.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

UBS Group first reported a position in LKFT in Q2 2015 and has held it in 44 quarters since. The position peaked at $11.4M in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • UBS Group held 175,289 shares of Lakefront Biotherapeutics American Depositary Shares worth $5.26M as of Q1 2026.
  • UBS Group sold 174,155 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $5.77M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4036 holding.
  • UBS Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 44 quarters since.
  • UBS Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $11.4M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.